American Heart Journal
Volume 153, Issue 1 , Pages 98-104 , January 2007

Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure

  • Uri Elkayam, MD

      Affiliations

    • University of Southern California, Los Angeles, CA
    • Corresponding Author InformationReprint requests: Uri Elkayam, MD, Heart Failure Program, USC School of Medicine, 2025 Zonal Ave, GH 7440, Los Angeles, CA 90033.
    • ,
  • Gudaye Tasissa, PhD

      Affiliations

    • Duke Clinical Research Institute, Duke University Medical Center, Durham, NC
    • ,
  • Cynthia Binanay, RN, BSN

      Affiliations

    • Duke Clinical Research Institute, Duke University Medical Center, Durham, NC
    • ,
  • Lynne W. Stevenson, MD

      Affiliations

    • Brigham and Women's Hospital, Boston, MA
    • ,
  • Mihai Gheorghiade, MD

      Affiliations

    • Northwestern University, Feinberg School of Medicine, Chicago, IL
    • ,
  • J. Wayne Warnica, MD

      Affiliations

    • University of Calgary, Calgary, Alberta, Canada
    • ,
  • James B. Young, MD

      Affiliations

    • Cleveland Clinic Foundation, Cleveland, OH
    • ,
  • Barry K. Rayburn, MD

      Affiliations

    • University of Alabama at Birmingham, Birmingham, AL
    • ,
  • Joseph G. Rogers, MD

      Affiliations

    • Duke Clinical Research Institute, Duke University Medical Center, Durham, NC
    • ,
  • Teresa DeMarco, MD

      Affiliations

    • University of California at San Francisco Medical Center, San Francisco, CA
    • ,
  • Carl V. Leier, MD

      Affiliations

    • The Ohio State University, College of Medicine and Public Health, Columbus, OH

Received 31 May 2006 ,Accepted 20 September 2006.

References 

  1. Elis A, Bental T, Kimchi O, et al. Intermittent dobutamine treatment in patients with chronic refractory congestive heart failure: a randomized, double-blind, placebo-controlled study. Clin Pharmacol Ther. 1998;63:682–685
  2. Oliva F, Latini R, Politi A, et al. Intermittent 6-month low-dose dobutamine infusion in severe heart failure: DICE multicenter trial. Am Heart J. 1999;138:247–253
  3. O'Connor CM, Gattis WA, Uretsky BF, et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J. 1999;138:78–86
  4. Cuffe MS, Califf RM, Adams KF, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA. 2002;287:1541–1547
  5. Felker GM, Benza RL, Chandler AB, et al. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol. 2003;41:997–1003
  6. Coletta AP, Cleland JG, Freemantle N, et al. Clinical trials update from the European Society of Cardiology Heart Failure meeting: SHAPE, BRING-UP 2 VAS, COLA II, FOSIDIAL, BETACAR, CASINO and meta-analysis of cardiac resynchronisation therapy. Eur J Heart Fail. 2004;6:673–676
  7. Cleland JG, Ghosh J, Freemantle N, et al. Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure. Eur J Heart Fail. 2004;6:501–508
  8. Shah MR, O'Connor CM, Sopko G. Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE): design and rationale. Am Heart J. 2001;141:528–535
  9. The ESCAPE Investigators and ESCAPE Study Coordinators. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. Presented November 9, 2004 at American Heart Association Annual Scientific Sessions, Late-Breaking Clinical Trials III; New Orleans, Louisiana.
  10. Thackray S, Easthaugh J, Freemantle N, et al. The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure—a meta-regression analysis. Eur J Heart Fail. 2002;4:515–529
  11. Abraham WT, Adams KF, Fonarow GC, et al. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry. J Am Coll Cardiol. 2005;46:57–64
  12. Arnold LM, Carroll NV, Oinonen M, et al. Mortality and length of hospital stay in patients receiving dobutamine, milrinone, or nesiritide for acute decompensated heart failure. J Card Fail. 2004;10:S103
  13. Fonarow GC, Adams KF, Abraham WT, et al. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA. 2005;293:572–580

 This study was supported by the National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.

PII: S0002-8703(06)00826-X

doi: 10.1016/j.ahj.2006.09.005

American Heart Journal
Volume 153, Issue 1 , Pages 98-104 , January 2007

Article Tools

* Image Usage & Resolution